Design and Rationale of the SALWEEN Trial: A Phase 3b/4 Study of Faricimab▼ , a Dual Angiopoietin-2 and Vascular Endothelial Growth Factor-A Inhibitor, in Patients With Polypoidal Choroidal Vasculopathy
This presentation describes the rationale and design of the phase 3b/4 SALWEEN study. SALWEEN will investigate the efficacy, safety and durability of faricimab▼ in patients in Asia with polypoidal choroidal vasculopathy (PCV), a subtype of nAMD highly prevalent in Asia and a population underrepresented in the phase 3 TENAYA/LUCERNE trials.